Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America

12 Jan 2026 07:00 CET

Issuer

FAGRON S.A.

Regulated information - inside information
Nazareth (Belgium)/Rotterdam (The Netherlands), 12 January 2026 – 7:00 AM CET

Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America

Fagron, the leading global player in pharmaceutical compounding, is pleased to announce the completion of University Compounding Pharmacy (UCP), a 503A pharmaceutical compounder focused on the health and wellness segment in California. The transaction was previously announced in September 2025 and has now closed following customary clearance.

UCP is based in San Diego and has strong positions in hormones and urology, alongside a solid compliance record. The business is highly complementary to Anazao and supports Fagron’s strategy to build a nationwide platform in the United States, spanning both 503A (patient specific) and 503B (outsourcing) services.

The acquisition also strengthens Fagron’s position in California, one of the largest and most tightly regulated healthcare markets in the United States, where licenses are difficult to obtain.

As previously disclosed, the enterprise value of the acquisition is c.$41.5 million, with annual revenues of around $25 million and an EBITDA margin below Fagron’s existing group margin. Fagron expects to realise synergies over the next 18 to 24 months as the business is integrated into its operations.

Over recent months, Fagron has executed fourteen acquisitions across all regions, with selective expansion into Asia-Pacific. Injeplast, MagiLab, Vepakum and Amber remain pending closing.

Rafael Padilla, CEO of Fagron, commented:
“Completing UCP is another concrete step in building a scaled, high-quality compounding platform in the United States. UCP adds attractive therapeutic depth, brings a strong compliance track record, and fits well alongside Anazao as we strengthen our footprint from coast to coast across both 503A and 503B.

Across the Group, we have strengthened our positions in core markets, expanded selectively into attractive new geographies, and added capabilities that deepen our vertical integration. We will remain selective and focused on execution as we integrate these businesses and continue to build a larger, higher-quality platform.”

Financial calendar
12 February 2026 Full year results 2025
9 April 2026 Trading update first quarter 2026
11 May 2026 Annual General Meeting 2025
30 July 2026 Half year results 2026
8 October 2026 Trading update third quarter 2026

Results and trading updates are published at 7.00 AM CET.

Further information
Ignacio Artola
Global Investor Relations Leader
Tel. +34 670385795
ignacio.artola@fagron.com

About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment